Philip Connell, MD, is an expert in radiotherapy with a particular focus on sarcomas, thoracic cancers, and pediatric malignancies. This year he was again recognized by Newsweek as one of “America's Top Doctors” and by Chicago Magazine as a “Top Doctor” in the Chicagoland region.
In addition to his clinical responsibilities, Dr. Connell is an active cancer researcher. He received laboratory training in cancer biology through a National Cancer Institute fellowship. His oncology research program is working to identify molecular markers of treatment resistance and to develop new anti-cancer agents that can overcome these molecular hurdles. His newest ongoing projects involve several novel, high-throughput assays designed to identify potential drugs that modify DNA repair. With these systems, researchers have the potential to discover new chemical compounds with wide-ranging impacts--from improving present oncology therapies to blocking the mutagenic effects of chemotherapy and radiotherapy.
Dr. Connell has received several awards including the American Society of Clinical Oncology Merit Award, American Brachytherapy Society Research Award, Roentgen Society Research Award, Samuel Hellman Teacher of the Year Award, and American Society for Therapeutic Radiology and Oncology Junior Faculty Fellowship Award. He has authored numerous medical reports and textbook chapters, and he serves as a reviewer for numerous medical journals.
University of Chicago
Chicago, Il
NIH Research Fellow - Cancer research
2001
University of Chicago
Chicago, Il
Residency - Radiation Oncology
2000
St. Vincent’s Hospital
New York, NY
Internship - Internal medicine
1996
New York Medical College
Valhalla, NY
MD - Medicine
1995
Tufts University
Medford, MA
BS - Chemical engineering
1991
Team Approach: Management of Pathologic Fractures.
Team Approach: Management of Pathologic Fractures. JBJS Rev. 2023 Jan 01; 11(1).
PMID: 36722819
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer.
STK11 Inactivation Predicts Rapid Recurrence in Inoperable Early-Stage Non-Small-Cell Lung Cancer. JCO Precis Oncol. 2023 01; 7:e2200273.
PMID: 36603171
A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy.
A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy. NPJ Precis Oncol. 2022 Oct 14; 6(1):72.
PMID: 36241710
Noncanonical NF-?B factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy.
Noncanonical NF-?B factor p100/p52 regulates homologous recombination and modulates sensitivity to DNA-damaging therapy. Nucleic Acids Res. 2022 06 24; 50(11):6251-6263.
PMID: 35689636
Mechanisms of distinctive mismatch tolerance between Rad51 and Dmc1 in homologous recombination.
Mechanisms of distinctive mismatch tolerance between Rad51 and Dmc1 in homologous recombination. Nucleic Acids Res. 2021 12 16; 49(22):13135-13149.
PMID: 34871438
qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer.
qRT-PCR-based DNA homologous recombination-associated 4-gene score predicts pathologic complete response to platinum-based neoadjuvant chemotherapy in triple-negative breast cancer. Breast Cancer Res Treat. 2022 Jan; 191(2):335-344.
PMID: 34797456
Targeting Non-Canonical NF?B2 to Determine the Effects on Radiation Sensitization.
Targeting Non-Canonical NF?B2 to Determine the Effects on Radiation Sensitization. Int J Radiat Oncol Biol Phys. 2021 Nov 01; 111(3S):e229-e230.
PMID: 34700966
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer.
CDKN2A loss-of-function predicts immunotherapy resistance in non-small cell lung cancer. Sci Rep. 2021 10 08; 11(1):20059.
PMID: 34625620
Radiation-Induced Sarcoma After Heterotopic Ossification Prophylaxis: A Case Report.
Radiation-Induced Sarcoma After Heterotopic Ossification Prophylaxis: A Case Report. JBJS Case Connect. 2019 Dec; 9(4):e0146.
PMID: 31815809
Elevated Radiation Therapy Toxicity in the Setting of Germline PTEN Mutation.
Elevated Radiation Therapy Toxicity in the Setting of Germline PTEN Mutation. Pract Radiat Oncol. 2019 Nov; 9(6):492-495.
PMID: 31185301
Best basic/translational science
Annual Meeting of the American Society for Radiation Oncology
2016
Recognized as one of “America's Top Doctors”
Newsweek
2015 - 2021
Recognized as a “Top Doctor”
Chicago Magazine
2015 - 2021
American Society for Therapeutic Radiology and Oncology Junior Faculty
U Chicago
2004 - 2005
Samuel Hellman Teaching Award
U Chicago
2003
Young Investigator Grant Award
Cancer Research Foundation
2001
Roentgen Society Research Award
Roentgen Society
1999
American Brachytherapy Society Research Award
American Brachytherapy Society
1999
American Society of Clinical Oncology Merit Award
American Society of Clinical Oncology
1997